Form 4: 22nd Century Group VP Acquires Shares and Stock Options

Sentiment:

SEC Form 4


Jonathan Staffeldt, VP and Deputy General Counsel of 22nd Century Group, reports acquisition of common stock and stock options.

Summary

  • On March 10, 2025, Jonathan Staffeldt, VP and Deputy General Counsel of 22nd Century Group, acquired 16,684 shares of common stock at $0 and 50,054 stock options with an exercise price of $2.01.
  • Following the transaction, Staffeldt directly owns 16,690 shares of common stock and 50,054 stock options.
  • The restricted stock units vest in three equal installments on March 10, 2026, 2027, and 2028, contingent upon continued service with the company.
  • The options vest in three equal installments on the anniversary of the grant date, contingent upon continued service with the company, and expire on March 10, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing insider transactions. The acquisition of shares and options could be interpreted as a slightly positive signal, but it's not definitive.

Positives

  • The acquisition of shares and options by a company officer could be seen as a positive sign of confidence in the company's future.

Future Outlook

The vesting schedules for the restricted stock units and stock options are contingent upon continued service with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

  • Stock option grants are a common form of executive compensation across various industries.
  • Vesting schedules, such as the 1/3 per year structure, are standard practice to incentivize long-term commitment from employees.
  • The specifics of the grant (number of options, exercise price, vesting schedule) would need to be compared to peer companies in the tobacco or biotech industry to assess its competitiveness.

Stakeholder Impact

  • The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the VP and Deputy General Counsel.

Key Dates

DateDescription
03/10/2025Date of transaction: acquisition of common stock and stock options
03/10/2026First vesting date for 1/3 of restricted stock units
03/10/2027Second vesting date for 1/3 of restricted stock units
03/10/2028Final vesting date for 1/3 of restricted stock units
03/10/2035Expiration date of stock options
03/12/2025Date of signature for the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.